Bexarotene: Targretin®;Bexarotène: Targretin®

Annales de Dermatologie et de Venereologie

Volumn 134, Issue 12, 2007, Pages 987-991

  Beylot Barry, M ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; CLARITHROMYCIN; DEXAMETHASONE; ERYTHROMYCIN; FENOFIBRATE; GEMFIBROZIL; GLITAZONE DERIVATIVE; INSULIN; KETOCONAZOLE; METRONIDAZOLE; ORAL CONTRACEPTIVE AGENT; PHENOBARBITAL; PHENYTOIN; RETINOL; RIFAMPICIN; SULFONYLUREA DERIVATIVE; ANTINEOPLASTIC AGENT; TETRALIN DERIVATIVE;

ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CD8+ T LYMPHOCYTE; DEPRESSION; DERMATOLOGY; DIABETES MELLITUS; DIARRHEA; DOSIMETRY; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DYSLIPIDEMIA; EYE TOXICITY; HUMAN; HYPERLIPIDEMIA; HYPOTHYROIDISM; MYALGIA; NAUSEA; NEUROTOXICITY; PANCREATITIS; PEDIATRICS; PERIPHERAL EDEMA; PRESCRIPTION; SKIN DISEASE; SKIN TOXICITY; SKIN TUMOR;

ANTINEOPLASTIC AGENTS; HUMANS; SKIN NEOPLASMS; TETRAHYDRONAPHTHALENES;

EID: 38049103433     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0151-9638(07)78263-7     Document Type: Article

References (7)

1. Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, et al. Phase 2 and 3 clinical trial of oral bexarotene for the treatment of refractory or persistant early stage cutaneous T-cell lymphoma. Arch Dermatol 2001;137:581-93.
2. Duvic M, Hymes K, Heald P, Beneman D, Martin AG, Myskowski P, et al. Bexarotene is effective and safe for the treatment of refractory advanced cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001;19:2456-71.
3. Trautinger F, Knobler R, Willemze R, Peris K, Stadler R, Laroche L, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 2006;42:1014-30.
4. Bachelez H, Bagot M, Beylot-Barry M, Claudy A, Grange F, Grob JJ, et al. Algorithme thérapeutique des lymphomes T cutanés. Ann Dermatol Venereol 2005;132-S2:43-4.
5. http://www.emea.europa.eu/humandocs/Humans/EPAR/targretin/targretin.htm
6. Talpur R, Ward S, Apisarnthanarax N, Brueer-Mc Ham J, Duvic M. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2002;47:672-84.
7. Gniadecki R, Assaf C, Bagot M, Dummer R, Duvic M, Knobler R, et al. The optimal use of bexarotene in cutaneous T-cell lymphoma Br J Dermatol 2007;157:433-40.